[Osteoporosis: from cost-effect characteristics to clinical efficacy and safety of strontium ranelate (bivalos)].
Dydykina
I S
IS
Tsurko
V V
VV
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy* / Q000191:economics*; D011379:Prognosis; D013876:Thiophenes / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate